These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 22416372)

  • 1. [Experience in complex therapy ribavine chronic viral hepatitis C].
    Domashenko OM
    Lik Sprava; 2011; (3-4):101-3. PubMed ID: 22416372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response-guided therapy: optimizing treatment now and in the future.
    Marcellin P; Rizzetto M
    Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
    [No Abstract]   [Full Text] [Related]  

  • 3. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2.
    Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
    Hepatology; 2008 Jul; 48(1):342. PubMed ID: 18506849
    [No Abstract]   [Full Text] [Related]  

  • 5. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
    Gerner P; Hilbich J; Wenzl TG; Behrens R; Walther F; Kliemann G; Enninger A; Wirth S
    J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):187-90. PubMed ID: 20512050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience with ronkoleukin and alfaferon combination in complex chronic hepatitis C treatment].
    Popova LL; Suzdal'tsev AA; Konstantinov DIu; Golik OO; Vasil'ev SIu
    Eksp Klin Gastroenterol; 2011; (6):102-7. PubMed ID: 22168088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. End of treatment response in chronic hepatitis C patients treated with interferon alpha and ribavirin.
    Tanveer A; Khalid SR; Kazmi SY; Faheem S
    J Coll Physicians Surg Pak; 2013 Oct; 23(10):764-5. PubMed ID: 24112272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment].
    Zoulim F
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B225-30. PubMed ID: 12180293
    [No Abstract]   [Full Text] [Related]  

  • 10. Interferon and ribavirin combination therapy: indications and schedules.
    Weiland O
    Forum (Genova); 2000; 10(1):22-8. PubMed ID: 10717255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficiency of enterosorbent White Coal in the treatment of the patients with chronic viral hepatitis C and its influence on lipoperoxidation markers and endogenous intoxication in blood of patients].
    Frolov VM; Sotskaia IaA; Kruglova OV
    Lik Sprava; 2012; (5):119-25. PubMed ID: 23534280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study.
    Tan AC; Brouwer JT; Glue P; van Leusen R; Kauffmann RH; Schalm SW; de Vries RA; Vroom B
    Nephrol Dial Transplant; 2001 Jan; 16(1):193-5. PubMed ID: 11209032
    [No Abstract]   [Full Text] [Related]  

  • 13. Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone.
    Cuccorese G; Tursi A; Spinazzola AM; Modeo ME; Miglietta A
    Am J Gastroenterol; 2000 Sep; 95(9):2399-400. PubMed ID: 11007262
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chronic hepatitis C. Chances of healing good as never before].
    MMW Fortschr Med; 2003 Oct; 145(42):61. PubMed ID: 14655449
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of patients with chronic hepatitis C who never had been treated].
    Hézode C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B38-49. PubMed ID: 12180307
    [No Abstract]   [Full Text] [Related]  

  • 16. Infectious disease. Despite setbacks, optimism on drugs for hepatitis C.
    Cohen J
    Science; 2012 Sep; 337(6101):1450-1. PubMed ID: 22997303
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic hepatitis C--Swedish experts' meeting recommends combination treatment.
    Wejstål R; Fischler B; Glaumann H; Norkrans G; Reichard O; Sönnerbor A; Uhnoo I; Weiland O; ;
    Scand J Infect Dis; 2000; 32(5):465-70. PubMed ID: 11055647
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment for hepatitis C virus associated cryoglobulinemia with interferon alpha and ribavirin].
    Altuna L; Fernández J; Castiella A
    Rev Esp Enferm Dig; 2005 Jul; 97(7):531-2. PubMed ID: 16262533
    [No Abstract]   [Full Text] [Related]  

  • 19. [Chronic viral hepatitis].
    Serov VV; Aprosina ZG; Ignatova TM; Krel' PE; Sekamova SM; Tanashchuk EL; Il'iankova AA
    Vestn Ross Akad Med Nauk; 2003; (4):34-8. PubMed ID: 12741358
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring treatment response by the hepatitis C virus core antigen assay.
    Lindh M; Lagging M; Westin J; Wejstål R; Norkrans G
    Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):230-2. PubMed ID: 15772819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.